Service de chirurgie générale et digestive Hôpital Saint-Antoine. [cited 2014 Feb 24] Available from: http://chirurgie-digestive-sat ,
Etude de modalités multithérapeutiques et diagnostiques appliquées au cancer du pancréas, Thèse de doctorat : Aspects moléculaires et cellulaires de la biologie, 2005. ,
Ostéopathie -Physiologie --Partie 5 : Le pancréas [Internet], 2014. ,
Physiopathologie du pancréas : Rôle de l'inflammation dans la cancérogenèse du pancréas exocrine, 2013. ,
Available from: http://www.med.univ- rennes1.fr/cerf Therapeutic targeting of pancreatic stroma, Pancreatic Cancer and Tumor Microenvironment [Internet]. Trivandrum (India): Transworld Research Network, 2014. ,
Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes, The Journal of Pathology, vol.487, issue.3, pp.107-124 ,
DOI : 10.1002/path.4172
Pancreatic cancer microenvironment, International Journal of Cancer, vol.3, issue.4, pp.699-705, 2007. ,
DOI : 10.1002/ijc.22871
Genetics and biology of pancreatic ductal adenocarcinoma, Genes & Development, vol.20, issue.10, pp.1218-1267, 2006. ,
DOI : 10.1101/gad.1415606
Roles for KRAS in Pancreatic Tumor Development and Progression, Gastroenterology, vol.144, issue.6, pp.1220-1229, 2013. ,
DOI : 10.1053/j.gastro.2013.01.071
Pancreatic Cancer: Advances in Treatment, Results and Limitations, Digestive Diseases, vol.31, issue.1, pp.51-57, 2013. ,
DOI : 10.1159/000347178
Current concepts and novel targets in advanced pancreatic cancer, Gut, vol.62, issue.2, pp.317-343, 2013. ,
DOI : 10.1136/gutjnl-2012-303588
Service de chirurgie générale et digestive Hôpital Saint-Antoine ,
Duodénopancréatectomie céphalique : indications, résultats et prise en charge des complications, Chirurgie, vol.163, issue.25, pp.1563-1569, 2008. ,
Conséquences fonctionnelles de la chirurgie pancréatique. Hépato-Gastro, Nov, vol.229, issue.6, pp.417-443, 2002. ,
Service de chirurgie générale et digestive Hôpital Saint-Antoine Available from: http://chirurgie-digestive-sat.aphp.fr/chirurgie/pancreatectomies/pancreatectomie-totale/ 21, AM. Therapeutic advances in pancreatic cancer. Gastroenterology, pp.1316-1342, 2013. ,
Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group, Cancer, vol.47, issue.8, pp.1705-1715, 1981. ,
DOI : 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer, New England Journal of Medicine, vol.350, issue.12, pp.1200-1210, 2004. ,
DOI : 10.1056/NEJMoa032295
Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg, pp.829-838, 2009. ,
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study, Annals of Oncology, vol.19, issue.9, pp.1592-1601, 2008. ,
DOI : 10.1093/annonc/mdn281
URL : https://hal.archives-ouvertes.fr/hal-00363727
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages, PLoS Medicine, vol.23, issue.4, 2010. ,
DOI : 10.1371/journal.pmed.1000267.s005
Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies, Annals of Surgical Oncology, vol.13, issue.5, pp.1644-62, 2012. ,
DOI : 10.1245/s10434-011-2110-8
Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials, Surgery, vol.150, issue.3, pp.466-73, 2011. ,
DOI : 10.1016/j.surg.2011.07.006
Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary Region, Annals of Surgery, vol.230, issue.6, pp.776-782, 1999. ,
DOI : 10.1097/00000658-199912000-00006
Conventional Chemotherapy of Advanced Pancreatic Cancer, Current Drug Targets, vol.13, issue.6, pp.795-801 ,
DOI : 10.2174/138945012800564149
-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial, Journal of Clinical Oncology, vol.29, issue.34, pp.4548-54, 2011. ,
DOI : 10.1200/JCO.2011.36.5742
URL : https://hal.archives-ouvertes.fr/hal-00261277
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer, Current Oncology Reports, vol.23, issue.Suppl 9, pp.182-191 ,
DOI : 10.1007/s11912-012-0290-4
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial, Journal of Clinical Oncology, vol.31, issue.1, pp.23-32, 2013. ,
DOI : 10.1200/JCO.2012.44.4869
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work, Nature Reviews Cancer, vol.196, issue.7, pp.487-93, 2012. ,
DOI : 10.1038/nrc3298
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development, Journal of Clinical Oncology, vol.17, issue.11, pp.3631-52, 1999. ,
DOI : 10.1200/JCO.1999.17.11.3631
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts, Cancer Biology & Therapy, vol.3, issue.12, pp.1217-1241, 2004. ,
DOI : 10.4161/cbt.3.12.1221
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA, Annals of Oncology, vol.23, issue.11, pp.2812-2832, 2012. ,
DOI : 10.1093/annonc/mds134
Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis, The Journal of Pathology, vol.35, issue.suppl???2, pp.4-7 ,
DOI : 10.1002/path.4213
Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins, Pancreas, vol.28, issue.1, pp.38-44, 2004. ,
DOI : 10.1097/00006676-200401000-00006
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther, 2007. ,
Tumor-Stromal Interactions in Pancreatic Cancer, Critical Reviews?? in Oncogenesis, vol.18, issue.1 - 2, pp.135-51, 2013. ,
DOI : 10.1615/CritRevOncog.v18.i1-2.80
The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance, Current Molecular Medicine, vol.12, issue.3, pp.288-303, 2012. ,
DOI : 10.2174/156652412799218921
Pancreatic cancer???associated stroma production, The American Journal of Surgery, vol.194, issue.4, pp.84-86, 2007. ,
DOI : 10.1016/j.amjsurg.2007.05.004
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2094116
Stromal biology and therapy in pancreatic cancer, Gut, vol.60, issue.6, pp.861-869, 2011. ,
DOI : 10.1136/gut.2010.226092
The Hedgehog Pathway and Pancreatic Cancer, New England Journal of Medicine, vol.361, issue.21, pp.2094-2100, 2009. ,
DOI : 10.1056/NEJMcibr0905857
Fibroblasts in cancer, Nature Reviews Cancer, vol.59, issue.5, pp.392-401, 2006. ,
DOI : 10.1038/nrc1877
A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment, Gastroenterology, vol.144, issue.6, pp.1210-1219, 2013. ,
DOI : 10.1053/j.gastro.2012.11.037
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell, pp.418-447, 2012. ,
Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment, Current Pharmaceutical Design, vol.18, issue.17, pp.2404-2419, 2012. ,
DOI : 10.2174/13816128112092404
Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res, Feb, vol.168, issue.3, pp.918-944, 2008. ,
Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma, Gastroenterology, vol.145, issue.5, pp.1121-1153, 2013. ,
DOI : 10.1053/j.gastro.2013.07.025
Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res, pp.3007-3025, 2013. ,
Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay, Journal of Cell Science, vol.120, issue.3, pp.512-521, 2007. ,
DOI : 10.1242/jcs.03347
Type I Collagen Promotes the Malignant Phenotype of Pancreatic Ductal Adenocarcinoma, Clinical Cancer Research, vol.10, issue.21, pp.7427-7464, 2004. ,
DOI : 10.1158/1078-0432.CCR-03-0825
Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression, PLoS ONE, vol.30, issue.5, p.64566, 2013. ,
DOI : 10.1371/journal.pone.0064566.s001
The ??2??1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines, British Journal of Cancer, vol.52, issue.9, pp.1311-1320, 2006. ,
DOI : 10.1083/jcb.121.5.1141
Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res, pp.11745-53, 2006. ,
Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer, Oncogene, vol.92, issue.16, pp.2381-2386, 2007. ,
DOI : 10.1038/sj.onc.1210012
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines, Molecular Cancer, vol.8, issue.1, p.125, 2009. ,
DOI : 10.1186/1476-4598-8-125
Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells. Surgery, pp.804-818, 2007. ,
Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid, Gut, vol.61, issue.10, pp.1377-1386, 2012. ,
DOI : 10.1136/gutjnl-2012-302604
Suppression of matrix metalloproteinase-2 ??via RNA interference inhibits pancreatic carcinoma cell invasiveness and adhesion, World Journal of Gastroenterology, vol.15, issue.9, pp.1072-1080, 2009. ,
DOI : 10.3748/wjg.15.1072
Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma, Modern Pathology, vol.37, issue.11, pp.1128-1168, 2007. ,
DOI : 10.1038/modpathol.3800956
Periostin, a matrix specific protein, is associated with proliferation and invasion of pancreatic cancer, Oncol Rep, vol.25, issue.3, pp.709-725, 2011. ,
Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation, Journal of Clinical Pathology, vol.57, issue.11, pp.1151-1156, 2004. ,
DOI : 10.1136/jcp.2003.015818
Role of fibrillar Tenascin-C in metastatic pancreatic cancer, Int J Oncol, vol.34, issue.4, pp.1029-1065, 2009. ,
The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.1760, issue.8, pp.1217-1242, 1760. ,
DOI : 10.1016/j.bbagen.2006.03.021
Versican: a versatile extracellular matrix proteoglycan in cell biology, Current Opinion in Cell Biology, vol.14, issue.5, 2002. ,
DOI : 10.1016/S0955-0674(02)00375-7
Tumor-Derived Pancreatic Stellate Cells Promote Pancreatic Cancer Cell Invasion Through Release of Thrombospondin-2, Journal of Surgical Research, vol.156, issue.1, pp.155-60, 2009. ,
DOI : 10.1016/j.jss.2009.03.040
Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer, Journal of Gastrointestinal Surgery, vol.3, issue.4, 1999. ,
DOI : 10.1016/S1091-255X(99)80058-4
Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride, Cancer Biochem Biophys, vol.17, issue.12, pp.109-132, 1999. ,
The stromal compartments in pancreatic cancer: Are there any therapeutic targets?, Cancer Letters, vol.343, issue.2, pp.147-55, 2014. ,
DOI : 10.1016/j.canlet.2013.09.039
Inflammation and cancer, Nature, vol.2, issue.6917, pp.860-867, 2002. ,
DOI : 10.1006/cyto.1996.0074
Cancer-related inflammation, Nature, vol.342, issue.7203, pp.436-480, 2008. ,
DOI : 10.1038/nature07205
Inflammation and the development of pancreatic cancer, Surgical Oncology, vol.10, issue.4, pp.153-69, 2002. ,
DOI : 10.1016/S0960-7404(02)00015-4
Review: Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies Impact of tumour associated macrophages in pancreatic cancer, Cancer Treat Rev Nov Bmb Reports, vol.2346, issue.773, pp.131-139, 2013. ,
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth, Cancer Immunology, Immunotherapy, vol.181, issue.8, pp.1373-85, 2012. ,
DOI : 10.1007/s00262-011-1178-0
Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy, Cancer Immunology, Immunotherapy, vol.15, issue.23, pp.59-65, 2014. ,
DOI : 10.1007/s00262-013-1485-8
Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma, The Journal of Immunology, vol.169, issue.5, pp.2756-61, 1950. ,
DOI : 10.4049/jimmunol.169.5.2756
HYPOXIA AND ANGIOGENESIS IN PANCREATIC CANCER, ANZ Journal of Surgery, vol.5, issue.11, pp.830-872, 2006. ,
DOI : 10.1038/nm0295-149
Angiogenesis: A prognostic determinant in pancreatic cancer?, European Journal of Cancer, vol.47, issue.17, pp.2576-84, 1990. ,
DOI : 10.1016/j.ejca.2011.08.016
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, pp.1457-61, 2009. ,
Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer, Angiogenesis, vol.6, issue.1, pp.15-24, 2003. ,
DOI : 10.1023/A:1025803600840
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density, Cancer Res, issue.13, pp.615262-615269, 2001. ,
Involvement of Angiotensin II and Reactive Oxygen Species in Pancreatic Fibrosis, Pancreatology, vol.11, issue.2, pp.7-13, 2011. ,
DOI : 10.1159/000323478
Inhibition of renin???angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine, British Journal of Cancer, vol.23, issue.11, pp.1644-1652, 2010. ,
DOI : 10.1016/j.jhep.2009.04.011
The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice, Scandinavian Journal of Gastroenterology, vol.580, issue.5, pp.602-611, 2013. ,
DOI : 10.1038/sj.bjc.6605955
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels, Nature Communications, vol.22, p.2516, 2013. ,
DOI : 10.1038/nmeth.1475
URL : http://doi.org/10.1038/ncomms3516
Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells, Cancer Letters, vol.345, issue.1, pp.132-141, 2014. ,
DOI : 10.1016/j.canlet.2013.12.006
High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma, British Journal of Cancer, vol.66, issue.9, pp.1444-51, 2009. ,
DOI : 10.1038/sj.bjc.6605020
CXCL12???CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy, British Journal of Cancer, vol.19, issue.11, pp.1671-1680, 2010. ,
DOI : 10.1016/j.jss.2006.06.031
The Pancreas Cancer Microenvironment, Clinical Cancer Research, vol.18, issue.16, pp.4266-76, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-3114
Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res Off J Am Assoc Cancer Res, pp.5262-70, 2007. ,
TGF-?? inhibition enhances chemotherapy action against triple-negative breast cancer, Journal of Clinical Investigation, vol.123, issue.3, pp.1348-58, 2013. ,
DOI : 10.1172/JCI65416DS1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582135
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, pp.469-83, 2005. ,
Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms, PLoS ONE, vol.6, issue.11, p.27306, 2011. ,
DOI : 10.1371/journal.pone.0027306.g007
URL : http://doi.org/10.1371/journal.pone.0027306
Inhibition of the Hedgehog Pathway Targets the Tumor-Associated Stroma in Pancreatic Cancer, Molecular Cancer Research, vol.10, issue.9, pp.1147-57, 2012. ,
DOI : 10.1158/1541-7786.MCR-12-0022
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer, Gut, vol.62, issue.1, pp.112-132, 2013. ,
DOI : 10.1136/gutjnl-2012-302529
Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment, Molecular Cancer Therapeutics, vol.10, issue.11, pp.2135-2180, 2011. ,
DOI : 10.1158/1535-7163.MCT-11-0261
nab-Paclitaxel mechanisms of action and delivery, Journal of Controlled Release, vol.170, issue.3, pp.365-72, 2013. ,
DOI : 10.1016/j.jconrel.2013.05.041
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer, British Journal of Cancer, vol.29, issue.4, pp.926-959, 2013. ,
DOI : 10.1038/bjc.2013.415
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov, pp.260-269, 2012. ,
Desmoplastic Reaction Influences Pancreatic Cancer Growth Behavior, World Journal of Surgery, vol.255, issue.8, pp.818-843, 2004. ,
DOI : 10.1007/s00268-004-7147-4
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer, Proceedings of the National Academy of Sciences, vol.110, issue.30, pp.12325-12355, 2013. ,
DOI : 10.1073/pnas.1300415110
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma, Journal of Clinical Investigation, vol.121, issue.10, pp.4106-4123, 2011. ,
DOI : 10.1172/JCI42754DS1
CXCR2 Macromolecular Complex in Pancreatic Cancer: A Potential Therapeutic Target in Tumor Growth, Translational Oncology, vol.6, issue.2, pp.216-241 ,
DOI : 10.1593/tlo.13133
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science, pp.1612-1618, 2011. ,
Vaccines in cancer: GVAX??, a GM-CSF gene vaccine, Expert Review of Vaccines, vol.4, issue.3, pp.259-74, 2005. ,
DOI : 10.1586/14760584.4.3.259
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer, Journal of Immunotherapy, vol.36, issue.7, pp.382-391, 1997. ,
DOI : 10.1097/CJI.0b013e31829fb7a2
Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>??</sup>) in the Palliative Treatment of Pancreatic Cancer, Current Medicinal Chemistry, vol.20, issue.38, pp.4827-4862, 2013. ,
DOI : 10.2174/09298673113206660290
Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma, Cancer Immunology, Immunotherapy, vol.82, issue.6, pp.1083-91 ,
DOI : 10.1007/s00262-013-1407-9
Immunotherapeutic benefit of ?interferon (IFN?) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients, Cancer Sci, 2013. ,
The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis, Immunology, vol.70, issue.2 Pt 2, pp.221-259, 2011. ,
DOI : 10.1111/j.1365-2567.2011.03429.x
The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer, Clinical Cancer Research, vol.14, issue.15, pp.4951-60, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-0157
Inhibition of the growth of patientderived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib, pp.143-55 ,
Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors, Clinical Cancer Research, vol.20, issue.5, pp.1212-1234, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-1897
Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations. Ther Adv Gastroenterol, pp.412-421, 2013. ,
Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene, pp.1367-74, 2014. ,
DOI : 10.1038/onc.2013.100